Active Trials

Attenuon is currently conducting clinical trials on ATN-224 and ATN-161. Click on the links below for further information about these trials.

ATN-161

Glioma:  A Phase I/II Study of ATN 161 and Carboplatin in Adult Patients with Recurrent Intracranial Malignant Glioma

ATN-224

Multiple Myeloma:  A Phase I/II Study of ATN-224 and Bortezomib in Patients with Multiple Myeloma Relapsed from or Refractory to Bortezomib

Advanced Melanoma:  A randomized phase II trial of ATN-224 in combination with temozolomide or temozolomide followed by ATN-224 in systemic- treatment naïve patients with advanced melanoma

Prostate Cancer:  Randomized, Phase II Study of Two Dose Levels of ATN-224 in Patients With Biochemically Relapsed, Hormone-Naïve Prostate Cancer

Breast Cancer:  A Cancer Research UK Randomised Phase II Trial of ATN-224 (Copper Binding Agent) in Combination with Letrozole versus Letrozole Alone in Post-menopausal Women with Recurrent, Oestrogen and/or Progesterone Receptor Positive Breast Cancer (PH2/053)